Investor sentiment toward Pfizer remains cautious despite a significant development in its dermatology pipeline. The pharmaceutical giant announced accelerated ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

The clearance in China comes weeks after Pfizer acquired rights to the therapy. Elsewhere, Alnylam is looking for “novel” cardiovascular targets and investors sold off Helus shares.

(Reuters) -U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm ...

Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical ...

Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...

Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of their leading drugs. Despite these challenges, Pfizer's resilience is highlighted by a robust ...

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions ...